Raises H1 guidance - Voyxact P3 data disclosure, R&D meeting set (August 4 at 09:00) CITI'S TAKE Otsuka announced a significant upward revision to H1 guidance before today's market open. The company raised H1 OP guidance from ¥175bn to ¥278bn. Q2 OP guidance reached ¥151.8bn, significantly exceeding consensus of ¥102.2bn. We view this positively. Contributing factors include lower generic impact, strong sales of Voyxact and Rexulti, yen depreciation, and under-budget R&D. Results will be announced on July 3 ...